ZGN enters its September 3 results with a notable shift underway in how the market is positioned — short sellers have pulled back sharply this week even as the stock itself drifts lower, creating an unusual divergence ahead of what has historically been a binary event.
The most striking development this week is the abrupt unwind in short positioning. Short interest fell 27% over the past week to 1.8% of the free float — a level low enough that it tells no dramatic story on its own, but the speed of the retreat is worth noting. From a peak near 6.4 million shares borrowed in mid-August, the position has collapsed to roughly 4.6 million. That's a meaningful cover in a stock trading at $13.73. Borrow costs have actually nudged higher through the move, up 27% on the week to 0.64%, though at that level they remain cheap in absolute terms. Availability is ample at 264% of short interest — well over twice the shares available to borrow relative to what's currently borrowed — so there's no mechanical pressure on remaining shorts. The ORTEX short score has also dropped from the low 60s to 57.4 this week, tracking the cover. Options traders, meanwhile, are skewing bullishly: the put/call ratio is 0.31, a touch above its 20-day average of 0.30 but nowhere near defensive territory. Taken together, positioning looks de-risked rather than charged.
The Street picture is more divided. Goldman Sachs downgraded the stock to Neutral in June, raising its target to $14 while stepping back from conviction. JP Morgan held its Overweight through the summer, lifting its target to $14 in late June. The most bullish voice is TD Cowen, which pushed its target to $17 in late July — the only analyst flagging meaningful upside from current levels. The consensus mean target of $12.87 actually sits below the current price of $13.73, which reflects how much the stock has run year-to-date (up roughly 35%). The bull case centres on Zegna's direct-to-consumer momentum and clienteling execution in its core brand. Bears point to persistent softness in Thom Browne and the Tom Ford segment still in investment mode, with wholesale rationalization incomplete and China recovery uneven. Valuation has compressed in line with the stock's one-month slide — the P/E multiple has shed about 2.8 points over 30 days to sit near 22.8x, and EV/EBITDA has pulled back to 7.8x. The dividend score ranks in the 99th percentile of the universe, an unusual distinction for a luxury name at this price.
The ownership structure is worth a glance. The founding Monterubello family controls 56.9% of shares and hasn't moved. Temasek holds another 10.2%, also unchanged. The meaningful recent shift is InvestIndustrial, which trimmed its 8.4% stake by 7 million shares as of June 30 — a sizeable reduction from a private equity holder that warrants attention. On the other side, T. Rowe Price added 557,000 shares and Amundi built a new position of 1.57 million shares, both reported through June. Insider activity from May — when the acting CEO, CFO, and other executives all sold small parcels at $13.12 following award grants — carries limited signal given the routine nature and low values involved.
Earnings history adds context. The May 2026 print produced a 2.6% one-day drop but recovered to flat by day five. The March 2026 results were the opposite: an 8.2% jump on the day that extended to 5.5% over the following week. The pattern suggests ZGN can move meaningfully in either direction, with the direction largely determined by the tone on China and Thom Browne progress. The September 3 print is close enough that the low PCR and rapidly falling short interest suggest the market is not positioning defensively — the next session after results will test whether that optimism is warranted or premature.
See the live data behind this article on ORTEX.
Open ZGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
